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Aim. To investigate the ability of Heidelberg Retina Tomograph (HRT3) Topographic Change Analysis (TCA) map to predict the
subsequent development of clinical change, in patients with glaucoma.Materials. 61 eyes of 61 patients, which, from a retrospective
review were defined as stable on optic nerve head (ONH) stereophotographs and visual field (VF), were enrolled in a prospective
study. Eyes were classified as TCA-stable or TCA-progressed based on the TCA map. All patients underwent HRT3, VF, and
ONH stereophotography at 9–12 months intervals. Clinical glaucoma progression was determined by masked assessment of ONH
stereophotographs and VF Guided Progression Analysis. Results. The median (IQR) total HRT follow-up period was 8.1 (7.3, 9.1)
years, which included a median retrospective and prospective follow-up time of 3.9 (3.1, 5.0) and 4.0 (3.5, 4.7) years, respectively.
In the TCA-stable eyes, VF and/or photographic progression occurred in 5/13 (38.4%) eyes compared to 11/48 (22.9%) of the TCA-
progressed eyes. There was no statistically significant association between TCA progression and clinically relevant (photographic
and/or VF) progression (hazard ratio, 1.18; 𝑃 = 0.762). The observed median time to clinical progression from enrollment
was significantly shorter in the TCA-progressed group compared to the TCA-stable group (𝑃 = 0.04). Conclusion. Our results
indicate that the commercially available TCA progression criteria do not adequately predict subsequent photographic and/or VF
progression.
1. Introduction
Accurate assessment of structural and functional change
in glaucoma is important for diagnosis and progression
detection. In current clinical practice, functional progression
is monitored by standard automated perimetry (SAP). Struc-
tural progression is subjectively determined by clinical eval-
uation of optic nerve head (ONH) stereophotographs [1–4].
Results from the Collaborative Initial Glaucoma Treatment
Study (CIGTS) and Ocular Hypertension Treatment Study
(OHTS) support the view that optic disc change may be a
more sensitive indicator of glaucomatous progression than
VF change in patients with glaucoma or ocular hypertension
(OHT) [5, 6]. However, in many cases VF defects were the
first sign of glaucomatous development in OHT eyes [5].
Objective technologies such as the Heidelberg Retina
Tomograph (HRT, Heidelberg Engineering, GmbH, Dossen-
heim, Germany) have been developed as adjuncts to subjec-
tive ONH evaluation. The HRT is a confocal scanning laser
tomography device that creates reproducible and repeatable
three-dimensional topographic images of the ONH and the
peripapillary retina [7].
The HRT software includes a commercially available
software package to help evaluate change over time called the
Topographic Change Analysis (TCA) map [8, 9].
The TCA map is an event-based technique for detecting
topographic surface height changes across the entire ONH
and peripapillary surface at a superpixel level between base-
line and follow-up images. Progression is identified when the
change exceeds measurement variability and is confirmed in,
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at least, 3 consecutive tests (error probability <5%). In the
currently available software (HRT3), progression is defined
as a cluster of 20 or more significantly depressed superpixels
[9, 10].
There is increasing evidence in the literature that TCA can
detect progressive optic disc changes [9, 11–14]. Additionally,
eyes with previous optic disc change by TCAmap were more
likely to have subsequent VF progression [15]. Nevertheless,
as our previous study and other studies have demonstrated,
there is a significant subset of patients who show TCA
changes without ONH stereophotograph [11–13] nor VF
progression [13].
The aim of this study was to determine, in a prospective
fashion, how well TCA maps are able to predict the subse-
quent development of ONH and/or VF changes.
2. Methods
2.1. Patients. This was a prospective cohort study that
enrolled clinically stable eyes with glaucoma. Subject recruit-
ment took place in the Glaucoma Unit of Toronto Western
Hospital, University Health Network, Toronto, Canada. Data
analysis and interpretation took place in the Glaucoma Units
of Toronto Western Hospital, and University of Athens,
Athens, Greece. In accordance with the Declaration of
Helsinki, patients gave informed consent to participate in the
study and the protocol was approved by theUniversityHealth
Network Research Ethics Board.
To identify clinically stable eyes a retrospective chart
review of all patients that had undergone ONH scanning
with HRT between 1997 and 2006 was performed. Inclusion
criteria were the following.
(1) Diagnosis of glaucoma: subjects were defined as
having glaucoma according to VF defects regardless
of the clinical appearance of the optic disc. Glauco-
matous VF defect was defined [16] by a Glaucoma
Hemifield Test (GHT) outside normal limits on at
least two VFs, or a cluster of three or more nonedge
points in a location typical for glaucoma, all of which
are depressed on the pattern deviation plot at a 𝑃 <
5% level and one of which is depressed at a 𝑃 < 1%
level on two consecutive VFs, or a pattern standard
deviation (PSD)with𝑃 < 5% level on two consecutive
VFs.
(2) Best corrected visual acuity >20/60.
(3) >2 years followup.
(4) ≥4 good-quality HRT examinations (SD ≤ 50);
(5) Reliable baseline VF (≤33% false positives, false nega-
tives, and fixation losses) performed within 8 months
of their first and most recent HRT examination.
(6) ONHstereophotographswithin 8months of their first
and most recent HRT examination.
Exclusion criteria were (1) systemic disease or systemic
medication known to affect the visual field; (2) refractive
error exceeding 5 diopters (equivalent sphere) of myopia or
hyperopia, or 3 diopters of astigmatism; and (3) concomitant
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stereophotographs and VFs > 8 months
Figure 1: Flow chart showing study exclusion process.
eye disease. If both eyes were eligible, one eye was randomly
chosen.
From a total of 1200 patients, 92 eyes of 92 patients met
the above criteria. ONH stereophotographs and VF tests of
those 92 patients were retrospectively evaluated to identify if
they had VF and/or photographic change (Figure 1).
After this initial retrospective evaluation, 61 eyes of 61
glaucoma patients were identified as clinically stable (stable
on bothONH stereophotographs andVFs) andwere enrolled
in a prospective study. At enrollment in the prospective
study, 27/61 clinically stable eyes were classified as TCA-
stable and 34/61 clinically stable eyes were classified as TCA-
progressed according to HRT3 progression criteria. During
the prospective period all patients underwent testing with
HRT3, SAP, and ONH stereophotographs at 9–12 months
intervals.
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Treatment changes were made in order to maintain target
IOP. As there is no published evidence to show TCA’s benefit
regarding initiation or change to treatment regimes, no
treatment changes were initiated based on TCA indications
for progression alone [11, 17].
2.2. Glaucoma Progression. The total followup consisted of
an initial (retrospective or preenrollment) and a subsequent
(prospective) followup with the objective of determining
how TCA change during the initial follow-up predicted
clinical progression during the subsequent followup. For all
three testing methods used in this study, progression was
determined by comparing the most recent examination to
the initial baseline using the progression criteria described
below. In the current study, clinical progression was defined
as aworsening onVFs and/orONH stereophotographs by the
following criteria.
2.2.1. HRT ONH Imaging. While HRTII software was used
for image acquisition in the preenrollment period, HRT3 was
used for image acquisition in the prospective period. HRT
image analysis, throughout the study period (retrospective
and prospective period), was performed by HRT3 software.
According to currently available TCA progression criteria,
progression was defined based on the largest cluster of
repeatable depressed superpixels (>20 superpixels) [10] with
statistically significant change within the optic disc-cluster
totally or partially inside the ONH margin. Progression
was not considered when the clusters of superpixels were
observed on ONH vessels [18, 19]. Additionally, HRT images
were checked for good alignment. Poor quality (SD > 50 𝜇m)
and misaligned images were excluded and the whole series
reprocessed. Throughout the study, eyes were classified as
TCA-progressed or TCA-stable based on the HRT3 TCA
results.
2.2.2. Stereoscopic Optic Disc Photography. All stereopho-
tographs were sequentially obtained with the same model
fundus camera (Topcon retinal camera TRC.50IX) by expe-
rienced technicians. Progressive change in stereophotographs
(focal or concentric rim thinning, increased vertical cup-to-
disc ratio, new or enlarged RNFL defect, or the presence of a
new disc hemorrhage) was defined as a clinical change in the
ONH.
Evidence of progression was based on masked compari-
son between the baseline and most recent stereophotograph,
independently by two experienced glaucoma specialists
(Trope and Buys) [11, 20]. Observers were masked to patient
identity, diagnosis, and the other observer’s results. The tem-
poral order of each photo pair was unmasked. Progression
was defined as a dichotomous variable (progression versus
no progression). Additionally, the observers were asked to
indicate the location where change had occurred. If the
observers disagreed, a consensus evaluation was undertaken.
2.2.3. Visual Field Testing. VFs were assessed for progression
by using criteria from the EarlyManifest Glaucoma Trial [21].
TheHumphrey Guided ProgressionAnalysis (GPA) was used
[22].
Progression on VFs was defined as “likely progression”
based on SAP GPA, requiring significant change in ≥3 points
in 3 consecutive follow-up VFs.
2.2.4. Statistical Analysis. Quantitative characteristics of the
study population were summarized through median and
interquartile range (IQR), whereas absolute and relative
frequencies were used to summarize categorical variables.
Descriptive characteristics were presented according to the
TCA status at enrollment date in the prospective study (Pro-
gressed or Stable). Comparisons between these two groups
were performed using Mann-Whitney 𝑈 tests and Fisher’s
exact tests for quantitative and qualitative characteristics,
respectively.
Differences in time-to-clinical (stereophotograph and/or
VF) progression according to TCA status were evaluated
through survival analysis techniques. More specifically, log-
rank tests and Cox proportional hazards models were used to
evaluate the prognostic value of TCA status along with other
factors.
Probability of clinical progression was estimated and
plotted using the Kaplan-Meier method. The focus of this
study was to see if TCA progression or TCA stability had
any influence on the subsequent development of clinically
detectable glaucomatous change. Therefore, enrollment date
in the prospective study (time-point when TCA status
became known) was used as the time origin for the survival
analyses.The TCA status was used as a time-updated variable
(time-varying covariate).
Interobserver reliability with respect to stereophotograph
evaluation was calculated by Cohen’s Kappa statistic; [23]The
Bias index (BI), the Prevalence index (PI), the Bias Adjusted
Kappa (BAK), and the Prevalence and Bias Adjusted Kappa
(PABAK) were also calculated [23–25].
A power analysis was performed to determine the small-
est hazard ratio for clinical progression that could be detected
with the current study size. For the primary outcome of VF
and/or ONH stereophotograph progression, given the num-
ber of TCA stable and TCA-progressed eyes at enrollment
and assuming an annual progression rate of 0.08 in the TCA
stable group (similar to EMGT) [26], the smallest hazard ratio
that could be detected with at least 80% power (at 𝛼 = 0.05
by 2-tailed test) was 3.3.
3. Results
Sixty-one clinically stable eyes of 61 patients with glaucoma
were included. Each study eye was classified as TCA-stable or
TCA-progressed. Demographic and clinical characteristics of
study patients/eyes are shown in Tables 1 and 2. At baseline,
53/61 eyes had earlyVF defects (MD> −6.0 dB), 6/61 eyes had
moderate VF defects (−6.0 dB >MD > −12.0 dB), and 2/61
eyes had advanced VF defects (MD < −12.0 dB) (Table 2).
Agreement between the two observers in the evaluation
of stereophotographs was moderate (proportion of observed
4 Journal of Ophthalmology
Table 1: Descriptive characteristics of study eyes/patients by HRT TCA status at enrollment.
TCA status at enrollment
TCA-stable 𝑛 (%) TCA-progressed 𝑛 (%) Overall 𝑛 (%) 𝑃 value
Total 27 (100.0) 34 (100.0) 61 (100.0)
Eye 0.43
OD 20 (74.1) 22 (64.7) 42 (68.9)
OS 7 (25.9) 12 (35.3) 19 (31.1)
Sex 0.89
Male 13 (48.1) 17 (50.0) 30 (49.2)
Female 14 (51.9) 17 (50.0) 31 (50.8)
Glaucoma type 0.96
POAG 14 (51.9) 18 (42.9) 32 (52.5)
LTG 8 (29.6) 9 (26.5) 17 (27.9)
CACG 2 (7.4) 2 (5.9) 4 (6.6)
PG 2 (7.4) 3 (8.8) 5 (8.2)
MMG 1 (3.7) 1 (2.9) 2 (3.3)
Axenfeld syndrome 0 (0.0) 1 (2.9) 1 (1.6)
HRT MRA (at baseline) 0.27
Within normal limits 7 (25.9) 14 (41.2) 21 (34.4)
Borderline 6 (22.2) 6 (17.6) 12 (19.7)
Outside normal limits 14 (51.9) 14 (41.2) 28 (45.9)
POAG: primary open angle glaucoma; LTG: low tension glaucoma; CACG: chronic angle closure glaucoma; PG: pigmentary glaucoma; MMG: mixed
mechanism glaucoma; MRA: moorfields regression analysis.
Table 2: Comparison of baseline and enrollment descriptive characteristics, in TCA-progressed (based on HRT TCA status at enrollment)
and TCA-stable eyes/patients.
TCA status at enrollment
TCA-stable TCA-progressed Overall
𝑃 value
Median (IQR) Median (IQR) Median (IQR)
Age at baseline (yrs) 55.3 (51.0, 61.6) 57.1 (53.3, 60.8) 56.5 (51.4, 60.8) 0.39
Age at enrollment (yrs) 59.2 (54.2, 65.5) 60.7 (58.3, 65.5) 60.3 (56.4, 65.5) 0.29
Preenrollment followup (yrs) 3.5 (2.8, 4.5) 4.4 (3.2, 5.3) 3.9 (3.1, 5.0) 0.09
VF exams, preenrollment period (𝑛) 5 (4, 6), range: 3–8 5 (4, 6), range: 3–11 5 (4, 6), range: 3–11 0.16
VF exams, prospective period (𝑛) 7 (6, 8), range: 3–13 7 (5.25, 8), range: 3–9 7 (6, 8), range: 3–13 0.36
HRT exams, preenrollment period (𝑛) 6 (5, 6), range: 4–10 6 (5, 7), range: 4–10 6 (5, 7), range: 4–10 0.11
HRT exams, prospective period (𝑛) 7 (5, 8), range: 2–11 7 (6, 8), range: 2–10 7 (6, 8), range: 2–11 0.14
CCT (𝜇m) 550.0 (525.0, 577.0) 548.0 (531.0, 565.0) 548.0 (530.0, 570.0) 0.96
MD at baseline (dB) −1.1 (−2.0, 0.1) −1.6 (−3.5, 0.0) −1.2 (−3.1, 0.0) 0.37
PSD at baseline (dB) 1.6 (1.3, 2.5) 1.9 (1.4, 2.8) 1.8 (1.4, 2.6) 0.22
VFI at baseline (%) 99.0 (98.0, 100.0) 98.0 (95.0, 99.0) 99.0 (96.0, 100.0) 0.17
GHT at baseline 1.0 (1.0, 3.0) 2.0 (1.0, 3.0) 1.0 (1.0, 3.0) 0.32
MRA at baseline 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 0.27
MD at enrollment (dB) −0.78 (−2.64, 0.15) −0.99 (−2.7, 0.08) −0.80 (−2.79, 0.03) 0.48
PSD at enrollment (dB) 1.53 (1.39, 2.08) 1.53 (1.39, 2.08) 1.77 (1.4, 2.4) 0.06
VFI at enrollment (%) 99 (98.5, 100) 98 (96, 99) 99 (97, 99) 0.09
Mean HRT topography SD at baseline (𝜇m) 17 (13.5, 22.5) 16 (11.0, 21.0) 16 (12, 21) 0.27
IQR: interquartile ranges; CCT: central corneal thickness; VF: visual field; MD: mean deviation; PSD: pattern standard deviation; VFI: visual field index; SD:
standard deviation; Stdev: standard deviation; GHT: glaucoma hemifield test (1.0: within normal limits, 2.0: borderline, and 3.0: outside normal limits); MRA:
moorfields regression analysis (1.0: within normal limits, 2.0: borderline, and 3.0: outside normal limits).
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34 eyes
TCA-progressed
61 eyes
clinically stable
27 eyes
TCA-stable
Baseline date
Retrospective period
Enrollment date
Prospective period
34 eyes
remained TCA-
progressed
14 eyes
converted to TCA-
progressed during 
 prospective followup
13 eyes
remained TCA-stable
for the whole followup
4 eyes
clinically progressed
⇒ 2 VF + SPG
⇒ 2 VF
30 eyes
clinically stable
7 eyes
clinically stable
7 eyes
clinically progressed
⇒ 1 VF + SPG
⇒ 6 SPG
8 eyes
clinically progressed
5 eyes
clinically progressed
⇒ 1 VF
⇒ 4 SPG
Figure 2: Study flow chart. VF: visual field; SPG: stereophotograph; TCA: Topographic change analysis.
agreement 𝑃o = 0.90 (95% confidence interval, CI): 0.86–
0.94), with Cohen’s kappa coefficient (𝑘) = 0.43 (95% CI:
0.23–0.63). The BI was −0.014, the PI was 0.81, the BAK was
0.43, and the PABAK was 0.81.
The median (IQR) absolute time difference between the
baseline HRT examination and baseline disc photograph was
0.27 (0, 0.87)months, and the baseline HRT examination and
baselineVFwas 0.23 (0, 1.37)months.Themedian (IQR) total
HRT followupwas 8.1 (7.0, 9.1) years, which includes amedian
preenrollment (or retrospective) and prospective follow-up
time of 3.9 (3.1, 5.0) and 4.0 (3.5, 4.7) years respectively
(Table 2). There were no statistically significant differences
in enrollment characteristics between TCA stable and TCA-
progressed eyes (Table 2).
Quality of HRT images was very good throughout the
total follow-up period (median (IQR) HRT topography SD
was 17 (13, 22)). Of the approximately 840 HRT images, only
7 had a SD between 40 and 50 𝜇m. The median (IQR) HRT
topography SD in the TCA-progressed group was 17 (13, 22)
and in the TCA-stable group was 16 (12, 19). A Kruskal-
Wallis analysis was performed that indicated a nonsignificant
difference between the two groups (H = 4.318, 1 d.f., 𝑃 =
0.038).
TCA progression was documented in 48/61 (78.7%) eyes
during the study but clinical progression (ONH stereophoto-
graph and/or VF change) was detected in only 16/61 (26.2%)
eyes.
Figure 1 shows the study selection and exclusion pro-
cess and Figure 2 details the prospective period in which
clinical progression (photographic ONH and/or VF change)
occurred in 5/13 (38.4%) TCA-stable eyes and in 11/48
(22.9%) TCA-progressed eyes.
The Kaplan-Meier cumulative probability of stereopho-
tograph and/or VF progression in eyes with previous TCA
progression was 18%, 20.5%, and 24.4% by 3, 4, and 5 years
after enrollment, respectively, compared with 0.0%, 26%, and
36.5% in TCA-stable eyes (Figure 3, Table 5).
Table 3 reports the hazard ratios (HRs) with 95% confi-
dence intervals (CIs) from univariate Cox models for each
potential predictive factor for glaucoma progression. TCA
progression was not associated with a statistically significant
increased risk of photographic and/or VF progression com-
pared with TCA stability (HR, 1.18; 𝑃 = 0.76). For any fixed
point in time, TCA-progressed eyes were at nearly four times
the risk of VF progression as TCA-stable eyes; however, this
was not statistically significant (HR 3.70; 𝑃 = 0.27).
Themedian survival time could not be computed because
less than half the subjects reached the event of inter-
est (stereophotograph and/or VF progression). Instead the
observed median times to stereophotograph and/or VF pro-
gression were calculated, for those who showed stereopho-
tograph and/or VF progression. The observed median time
to VF and/or stereophotograph progression from enrollment
was statistically significant shorter in the TCA-progressed
group compared to the TCA-stable group (Table 4).
In 9 eyes of our cohort, HRTI scans were used as
baseline images. Survival analyses were also performed,
after excluding the 9 eyes with HRTI baseline, which gave
similar results. More in detail, the Kaplan-Meier cumulative
probability of stereophotograph and/or VF progression in
eyes with previous TCA progression was 20.6%, 23.4%, and
6 Journal of Ophthalmology
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Figure 3: Kaplan-Meier curves for stereophotograph (SPG) and/or visual field (VF) progression (a), SPG only progression (b), and VF only
progression (c), from recruitment, by topography change analysis (TCA) status. 𝑃 values are from log-rank test.
28.2% by 3, 4, and 5 years after enrollment, respectively,
compared with 0.0%, 28.6%, and 40.5% in TCA-stable eyes
(log rank 𝑃 = 0.83). TCA progression was not associated
with a statistically significant increased risk of photographic
and/or VF progression compared with TCA stability (HR,
1.14; 𝑃 = 0.82).
4. Discussion
TCA-map has shown good ability to detect progressive
ONH changes [9, 11–14]. However, the clinical usefulness
of commercially available TCA progression criteria [10] is
significantly limited since a large subset of patients withONH
changes on TCAhas no clinically detectable change (22.2% to
55.4% of TCA progressing eyes) [9, 11].
In the present study, we investigated whether eyes with
TCA progression at enrollment, but no VF and ONH
stereophotograph change, were associatedwith increased risk
of subsequently developing clinically detectable glaucoma
progression based onVFGPA and expert assessment ofONH
stereophotographs. For this reason, we included eyes that had
neither photographic ONH nor functional progression for a
median retrospective follow-up period of 3.9 years (Table 2).
In addition, we should note the fact that we mostly enrolled
clinically stable eyes with early glaucomatous VF damage
(Table 2)—as a result of the patient selection process and the
availability of eligible patient—and, therefore, our resultsmay
not apply to glaucoma patients in general.
Although SAP and ONH stereophotographs may be
imperfect reference standards, they are widely used in clinical
practice and have been validated by major clinical trials
Journal of Ophthalmology 7
Table 3: Univariable Cox models for the hazard of glaucoma progression by TCA status and other potential prognostic factors.
Covariate
Stereophotograph
and/or Visual Field Stereophotographs Visual Fields
HR 95% CI 𝑃 HR 95% CI 𝑃 HR 95% CI 𝑃
TCA progression
Stable 1.00 1.00 1.00
Progressed 1.18 (0.39, 3.63) 0.76 0.99 (0.29, 3.36) 0.99 3.70 (0.37, 37.14) 0.27
Sex
Male 1.00 1.00 1.00
Female 1.52 (0.54, 4.33) 0.43 1.53 (0.48, 4.84) 0.47 3.56 (0.39, 32.63) 0.26
MRA at baseline
Within normal limits 1.00 1.00 1.00
Borderline 1.56 (0.36, 6.72) 0.55 2.35 (0.47, 11.73) 0.30 1.02 (0.10, 10.81) 0.99
Outside normal limits 1.05 (0.34, 3.24) 0.94 1.31 (0.33, 5.32) 0.70 0.45 (0.07, 2.76) 0.39
CCT (per 50 𝜇m thicker) 0.85 (0.46, 1.58) 0.61 0.90 (0.47, 1.74) 0.76 0.48 (0.16, 1.44) 0.19
MD at baseline (per 1 dB larger) 1.03 (0.88, 1.21) 0.69 1.08 (0.89, 1.32) 0.43 0.93 (0.75, 1.16) 0.53
PSD at baseline (per 1 dB larger) 1.03 (0.91, 1.17) 0.63 0.99 (0.85, 1.16) 0.92 1.13 (0.94, 1.37) 0.19
VFI at baseline (per 10 units) 0.99 (0.57, 1.73) 0.97 1.11 (0.56, 2.19) 0.77 0.77 (0.33, 1.78) 0.54
Age at baseline (per decade) 1.11 (0.62, 1.97) 0.73 1.13 (0.59, 2.16) 0.70 1.91 (0.54, 6.76) 0.31
Age at enrollment (per decade) 1.12 (0.64, 1.99) 0.68 1.15 (0.61, 2.17) 0.66 1.78 (0.53, 6.01) 0.35
Preenrollment followup (per year) 1.09 (0.78, 1.52) 0.61 1.08 (0.75, 1.55) 0.68 0.88 (0.42, 1.83) 0.73
Vertical c/d ratio at enrollment (per unit) 2.98 (0.16, 57.01) 0.47 3.98 (0.11, 138.27) 0.44 2.95 (0.03, 311.79) 0.65
Mean HRT topography SD at baseline (per 1 𝜇m) 1.04 (0.98, 1.11) 0.17 1.04 (0.97, 1.11) 0.27 1.05 (0.95, 1.15) 0.35
MRA: moorfields regression analysis; OHT: ocular hypertension; CCT: central corneal thickness; MD: mean deviation; PSD: pattern standard deviation; VFI:
visual field index; c/d: cup/disc; HR: hazard ratio; SD: standard deviation; CI: confidence interval; dots (.) denote nonestimable quantities.
Table 4: Median times to clinical (ONH stereophotograph and/or Visual Field) progression for TCA-stable and TCA-progressed eyes
throughout the whole followup.
Time (months)
Median (IQR)
𝑛
TCA-stable eyes
(𝑛 = 13) 𝑛
TCA-progressed eyes
(𝑛 = 48) 𝑃 value
Baseline to ONH SPG and/or VF progression 5 7.42 (6.88, 7.73) 11 7.94 (5.12, 8.52) 0.20
Baseline to ONH SPG progression 4 7.15 (6.84, 7.56) 9 7.94 (5.24, 8.74) 0.20
Baseline to VF progression 1 7.73 (7.73, 7.73) 5 5.01 (4.76, 8.07) 0.20
Enrollment to ONH SPG and/or VF progression 5 3.90 (3.36, 4.11) 11 2.31 (1.85, 3.51) 0.04
Enrollment to ONH SPG progression 4 3.63 (3.35, 3.95) 9 2.81 (1.96, 4.01) 0.20
Enrollment to VF progression 1 5.69 (5.69, 5.69) 5 1.85 (1.75, 2.18) 0.005
ONH: optic nerve head; TCA: topography change analysis; SPG: stereophotograph; VF: visual field; IQR: interquartile ranges; dots (.) denote nonestimable
quantities.
[27–29]. To the best of our knowledge, our study is the first
publication on ONH stereophotograph and VF progression
after longitudinally observed TCA change in patients with
stable glaucoma.
Our results indicate that current TCAprogression criteria
[10] do not successfully predict subsequent photographic
and/or VF progression as defined in this study. The pre-
dictive ability of TCA maps did not significantly improve
when different criteria were used to define progression (disc
stereophotographs, GPA, disc stereophotographs, and/or
GPA) (Figure 3, Table 5). The survival curves reveal that,
after 3 years of prospective followup, the TCA-progressed
group had a nonstatistically significant higher probability of
photographic and/or VF progression (Figure 3, Table 5).
Our previous work [11] tried to identify discrepan-
cies between TCA-progression and progression detected by
expert-assessed sequential disc stereophotographs. This 2.6
year retrospective study on 54 patients reported agreement
in only 65% of cases. A smaller proportion progressed on
stereophotograph assessment (6%, or 3 eyes) compared to
TCA (30%, or 16 eyes). Other studies [9, 12] comparing
longitudinal TCA and stereophotographs have also reported
that agreement between these 2 structural assessments is
moderate, with concordances of 81% and 44% to 71%
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Table 5: Kaplan-Meier cumulative probabilities of stereophotograph (SPG) and/or visual field (VF) progression, SPG only progression, and
VF only progression, from recruitment, by topography change analysis (TCA) status.
Stereophotograph and/or Visual Fields Stereophotographs Visual Fields
Time from
enrolment
(months)
TCA-stable
Mean (95% CI)
TCA-progressed
Mean (95% CI)
TCA-stable
Mean (95% CI)
TCA-progressed
Mean (95% CI)
TCA-stable
Mean (95% CI)
TCA-progressed
Mean (95% CI)
0 0.0 (.,.) 0.0 (.,.) 0.0 (.,.) 0.0 (.,.) 0.0 (.,.) 0.0 (.,.)
12 0.0 (.,.) 0.0 (.,.) 0.0 (.,.) 0.0 (.,.) 0.0 (.,.) 0.0 (.,.)
24 0.0 (.,.) 10.7 (4.1, 26.0) 0.0 (.,.) 7.8 (2.6, 22.3) 0.0 (.,.) 8.0 (2.6, 22.7)
36 0.0 (.,.) 18.0 (9.0, 34.0) 0.0 (.,.) 12.7 (5.5, 27.9) 0.0 (.,.) 10.5 (4.1, 25.5)
48 26.0 (9.0, 61.8) 20.5 (10.8, 36.7) 26.0 (9.0, 61.8) 15.3 (7.2, 30.9) 0.0 (.,.) 10.5 (4.1, 25.5)
60 36.5 (15.2, 71.6) 24.4 (13.3, 42.2) 36.5 (15.2, 71.6) 19.5 (9.6, 37.4) 00 (.,.) 10.5 (4.1, 25.5)
Dots (.) denote nonestimable quantities.
(depending on progression criteria). This could be attributed
to the fact that different methods possibly provide compli-
mentary progression information as illustrated in our cases
of disagreement (Figure 4).
Table 3 details univariate Cox’s models to investigate
the relationship between clinically relevant glaucoma pro-
gression and patient characteristics. TCA progression was
associated with an insignificant trendto increased risk for
clinically relevant glaucoma progression. All other evaluated
risk factors showed no significant prognostic effect. This
result could be due to the relatively small number of clinically
progressing eyes (16/61, 26.2%) in our cohort.
Data in Table 4 indicates that TCA change may be
associated with earlier clinical glaucoma progression. More
in detail, the observed median time to VF and/or ONH
stereophotograph progression from enrollment was signifi-
cantly shorter in the TCA-progressed group compared to the
TCA-stable group (𝑃 = 0.04). Given the small numbers,
the quality of available evidence is low and not suitable for
drawing conclusions. Chauhan et al. [15] recently showed, by
using a conservative TCA criterion, that mean time to VF
progression was statistically significantly shorter in patients
with previous TCA disc changes. Nevertheless, the predictive
ability of TCA progression was found to be rather weak with
more than 70% of the TCA progressing eyes not developing
VF progression when followed for more than 6 years after
TCA progression was detected [15].
Of concern was the fact that a significant number of
TCA stable patients (5/13, 38.4%) showed photographic
ONH or VF progression. In each case, TCA identified the
corresponding ONH area as being abnormal but with fewer
than 20 red superpixels (Figure 5). This suggests that in these
cases the TCA criteria were too conservative and may need
adjustment based on other factors such as disease severity or
location to detect progression.
Several differentmethods have been proposed to improve
the performance of the TCA technique to monitor pro-
gression, which are yet to be incorporated into the opera-
tional software. These include using TCA cutoffs, statistical
image mapping (SIM) technique, and proper orthogonal
decomposition [13, 30, 31]. O’Leary et al. [32] compared
change in HRT image series identified by 3 automated
statistical analytical methods (TCA, SIM, and ordinary least
squares linear regression of rim area (RALR)) with optic disc
stereophotographs assessments by glaucoma specialists. This
study showed poor agreement between glaucoma expert-
assessed stereophotographs and the 3 HRT statistical analy-
ses. At a fixed specificity of 90% for all 3methods, sensitivities
were 25% for TCA, 27% for SIM, and 40% for RALR.
Bowd et al. [13] introduced new TCA parameters and
suggested parameter cutoffs for detecting progression in
eyes with suspected or known primary open angle glau-
coma. When the best performing cutoffs were applied to
longitudinal topographic series obtained from patient eyes
observed for four or more years and showing no evidence
of progression based on SAP or stereophotographic assess-
ment, specificities were poor to moderate (from 0.464 for
CAREAdisc (area of a cluster, in mm2, within the optic disc
margin), with the 0.90 specificity cutoff of 0.036mm2, to
0.647, with the 0.99 specificity cutoff of 0.074mm2).
There are certain limitations that need to be acknowl-
edged and addressed regarding the present study. One limita-
tion of this and similar studies is the lack of a sufficiently inde-
pendent valid reference standard for progression.We decided
to employ structural and functional endpoints despite the
fact that the comparison of an imaging technology is likely
more relevant to photographic optic disc progression rather
than perimetry. The EMGT criterion for VF progression was
recently shown to have high specificity [28]. Nevertheless,
it may be the case that true progression is missed using
subjective stereophotograph assessment. Also, it is likely that
VF progression does not occur in temporal conjunction with
structural change, regardless of progression criteria.
Our observers’ agreement reviewing ONH stereopho-
tographs has been evaluated in previous studies [11, 20]
and is consistent with other studies [33–35]. Despite an
interobserver agreement of 90% (proportion of observed
agreement 𝑃o = 0.90 (95%, CI): 0.86–0.94), the kappa value
(kappa = 0.43) suggests moderate agreement. However,
the PABAK (0.81) revealed that kappa (0.43) was influenced
by the low prevalence of disc change as judged by either
observer and therefore it may be erroneous to conclude that
our observers’ ratings were unreliable [36].
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Figure 4: Case examples of disagreement for detecting glaucoma progression among Topographic Change Analysis (TCA) map, optic nerve
head (ONH) stereophotographs (SPGs), and Visual Fields (VFs). (a) Low tension glaucoma (LTG), OD, female. This eye was TCA-stable at
recruitment (2001). During the prospective followup it remained stable on both TCA and VF. Progression was found only on SPG (increased
cupping and inferior rim thinning). (b) Primary open angle glaucoma (POAG), OD, female. This eye was TCA-stable at recruitment (2001).
During the prospective followup it remained stable on both TCA and SPG. Progression was found only on VF. (c) POAG, OD, female. This
eye was TCA-progressed at recruitment (2000). During the prospective followup it remained stable on both VF and SPG. TCA showed
progression (superior and inferior rim thinning) throughout the study period.
Another limitation of this study is the fact that TCA
progression criteria included statistically significant clusters
of red superpixels located either totally or partially inside
the ONH margin. Clusters lying mostly outside the ONH
margin could probably not be detected clinically by looking
at optic disc stereophotos. Therefore, such a criterion could
induce false positive TCA-progressed patients. Nevertheless,
the commercially available HRT3 software, we used in the
current study, does not have the ability to delineate a sig-
nificant cluster of superpixels within the ONH margin if it
belongs to a larger cluster that is extended partially outside
the optic disc as well.
A possible weakness of this study is that theHRT software
was updated during the 8-year followup. Image acquisition
was performed by using HRTII in the preenrollment period
and HRT3 in the prospective period. In 9 eyes, HRTI scans
were used as baseline images. Image analysis however was
carried out in both pre-enrollment and prospective periods
by using onlyHRT3.TheHRT3 has the advantage of compati-
bility with the earlier versions allowing glaucoma progression
to be detected over a much longer time period [37]. Recent
evidence shows that in some eyes, TCA progression may be
overestimated when HRTI scans are used as baseline images
with HRTII scans as follow-up images [38]. In our cohort,
results from the survival analyses were similar after excluding
the 9 eyes with HRTI baseline.
Possible limitation also includes the fact that the current
study was powered to detect a large HR (HR ≥ 3.3) for
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Figure 5: Five out of 13 TCA-stable cases showing clinical progression. In all cases the HRT highlighted the corresponding optic nerve head
(ONH) area but with fewer than 20 superpixels. (a) Progression was found on inferior visual field (VF) hemifield (1a). The HRT highlighted
the correspondingONHarea—over the vessels (1b). (b) Progressionwas found on stereophotograph (SPG) (temporal (2a) and inferior (6) rim
thinning). TCA highlighted the temporal ONH area only (2b). (c), (d) and (e) Clinical progression in 3a, 4a, and 5a disc areas was highlighted
by TCA (3b, 4b, and 5b, resp.).
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development of clinical progression. Given the fact we did
not find that the expected association raises the possibility
that this could have been due to a small sample size and thus
our evaluationswere possibly underpowered.This is also sug-
gested by the fact that no other risk factor was associated with
clinical progression in the Cox proportional hazards analysis.
Nevertheless, theHRmagnitude that could be detected by our
study size was generally lower compared to hazard ratios for
the association between other HRT parameters (moorfields
regression analysis (MRA) and Glaucoma Probability Score
(GPS)) and the development of glaucoma progression in the
OHTS. Weinreb et al. [39] reported hazard ratios ranging
from 2.92 to 3.59 for the GPS global and regional parameters
outside normal limits compared with within normal limits,
and from 3.34 to 14.25 for the MRA global and regional
parameters outside normal limits compared with not outside
normal limits.
In conclusion, the identification of clusterwise significant
change needs clinical interpretation and possibly redefinition
of current progression criteria in order to take advantage of
themany practical advantages of theHRT.Our results suggest
that TCA progression on its own was associated with only a
statistically insignificant trendto increased risk for clinically
relevant glaucoma progression. It is possible that TCA ONH
change may be associated with earlier clinical glaucoma
progression but longer followup is required to prove this. In
addition, clinical change was found in nearly 40% of eyes
deemed stable by TCA. Although TCAmaps are widely used
there are currently only few suggestions as to what constitutes
clinically relevant change. Therefore, clinicians should not
rely on a single method to determine disease progression.
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